AR046753A1 - Derivados de benzoxazina y usos de los mismos - Google Patents
Derivados de benzoxazina y usos de los mismosInfo
- Publication number
- AR046753A1 AR046753A1 ARP040104555A ARP040104555A AR046753A1 AR 046753 A1 AR046753 A1 AR 046753A1 AR P040104555 A ARP040104555 A AR P040104555A AR P040104555 A ARP040104555 A AR P040104555A AR 046753 A1 AR046753 A1 AR 046753A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- haloalkyl
- independently
- atoms
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Composiciones que contienen estos compuestos, el uso de estos compuestos para la fabricación de medicamentos así como métodos para la obtención del compuesto de la fórmula (1). Reivindicación 1: Un compuesto de la fórmula (1), o una sal, solvato o profármaco farmacéuticamente aceptable del mismo, en la que: m es un número de 0 a 3; X es N o CH; Y es -SO2- o -CH2-; cada R1 con independencia de su aparición es halo, alquilo, haloalquilo, alcoxi, ciano, hidroxialquilo, alcoxialquilo, -SO2Ra, - C(=O)-NRbRc, -SO2-NRbRc, -SRb, -N(Rb)-C(=O)-Rc, -C(=O)-Rb, o -N(Rb)-SO2-Ra, en los que cada Ra con independencia de su aparición es alquilo o haloalquilo y cada uno de Rb y Rc con independencia entre sí es hidrógeno, alquilo o haloalquilo; R2 es arilo o heteroarilo opcionalmente sustituido por alquilo, halo, haloalquilo, alcoxi o ciano; cada uno de R3 y R4 con independencia entre sí es alquilo, hidroxialquilo o alcoxialquilo, o R3 y R4 junto con el átomo de carbono al que están unidos pueden formar un grupo cíclico de 3 a 6 átomos en el anillo que opcionalmente incluye un heteroátomo elegido entre N, O y S; y cada uno de R5, R6, R7, R8 y R9 con independencia entre sí es hidrógeno o alquilo, o R9 y uno de R5, R6, R7 y R8 junto con los átomos a los que están unidos forman un anillo heterocicloamino que tiene de 5 a 7 átomos en el anillo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52837803P | 2003-12-09 | 2003-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046753A1 true AR046753A1 (es) | 2005-12-21 |
Family
ID=34699863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040104555A AR046753A1 (es) | 2003-12-09 | 2004-12-07 | Derivados de benzoxazina y usos de los mismos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7202241B2 (es) |
| EP (1) | EP1694656B1 (es) |
| JP (1) | JP4527730B2 (es) |
| KR (1) | KR100827915B1 (es) |
| CN (1) | CN100532369C (es) |
| AR (1) | AR046753A1 (es) |
| AT (1) | ATE371653T1 (es) |
| AU (1) | AU2004299201B2 (es) |
| BR (1) | BRPI0416873A (es) |
| CA (1) | CA2547764A1 (es) |
| CO (1) | CO5700768A2 (es) |
| DE (1) | DE602004008668T2 (es) |
| ES (1) | ES2291984T3 (es) |
| IL (1) | IL175817A0 (es) |
| MY (1) | MY145576A (es) |
| NO (1) | NO20062491L (es) |
| NZ (1) | NZ547120A (es) |
| RU (1) | RU2354651C2 (es) |
| TW (1) | TW200522953A (es) |
| WO (1) | WO2005058847A1 (es) |
| ZA (1) | ZA200604725B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2453837C (en) * | 2001-07-20 | 2011-10-04 | Psychogenics, Inc. | Treatment for attention-deficit hyperactivity disorder using eltoprazine and related compounds |
| ES2359725T3 (es) * | 2004-09-30 | 2011-05-26 | F. Hoffmann-La Roche Ag | Composiciones y métodos para el tratamiento de trastornos cognitivos. |
| US7713954B2 (en) * | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| JP2009533325A (ja) * | 2006-03-17 | 2009-09-17 | アストラゼネカ・アクチエボラーグ | ５−ｈｔ６調節剤としての新規なテトラリン |
| CL2007003044A1 (es) * | 2006-10-24 | 2008-07-04 | Wyeth Corp | Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros. |
| WO2011023753A1 (en) * | 2009-08-27 | 2011-03-03 | Glaxo Group Limited | Benzoxazine derivatives as glycine transport inhibitors |
| CN101836993B (zh) | 2010-05-20 | 2011-06-22 | 山东大学 | 2，3-二氢-3-羟甲基-6-氨基-[1，4]-苯并噁嗪在制备诱导胚胎干细胞向血管内皮细胞分化药物中的应用 |
| CN102060810B (zh) * | 2010-12-20 | 2012-07-04 | 金坛市爱特生物科技有限公司 | 一种n-叔丁氧羰基-哌嗪的提纯方法 |
| MX2016010998A (es) | 2014-02-27 | 2017-03-31 | Lycera Corp | Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados. |
| EP3209641A4 (en) | 2014-05-05 | 2018-06-06 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease |
| CA2947290A1 (en) | 2014-05-05 | 2015-11-12 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| CN105541693B (zh) | 2014-07-08 | 2018-10-16 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
| JP2018515491A (ja) | 2015-05-05 | 2018-06-14 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物 |
| KR20180025894A (ko) | 2015-06-11 | 2018-03-09 | 라이세라 코퍼레이션 | Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료 |
| CN109568321B (zh) * | 2019-01-14 | 2022-02-22 | 山东轩竹医药科技有限公司 | RORγ调节剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8803419D0 (en) * | 1988-02-15 | 1988-03-16 | Erba Carlo Spa | 1 4-benzoxazine & 1 4-benzothiazine derivatives & process for their preparation |
| GB9507203D0 (en) | 1995-04-07 | 1995-05-31 | Smithkline Beecham Plc | Novel compounds |
| BR9809092A (pt) | 1997-04-18 | 2002-01-22 | Smithkline Beecham Plc | Derivados de indol tendo atividade combinada de antagonista de receptor de 5ht1a, 5ht1b e 5ht1d |
| US6380235B1 (en) | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Benzimidazolones and analogues |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| EP1255743A1 (en) | 2000-02-01 | 2002-11-13 | Millenium Pharmaceuticals, Inc. | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa |
| PL211057B1 (pl) * | 2002-05-13 | 2012-04-30 | Hoffmann La Roche | Pochodne benzoksazyny, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych benzoksazyny |
| CN100390157C (zh) * | 2002-11-08 | 2008-05-28 | 弗·哈夫曼-拉罗切有限公司 | 取代的苯并嗪酮及其用途 |
-
2004
- 2004-11-30 ES ES04820410T patent/ES2291984T3/es active Active
- 2004-11-30 NZ NZ547120A patent/NZ547120A/en unknown
- 2004-11-30 WO PCT/EP2004/013557 patent/WO2005058847A1/en active IP Right Grant
- 2004-11-30 AU AU2004299201A patent/AU2004299201B2/en not_active Ceased
- 2004-11-30 AT AT04820410T patent/ATE371653T1/de active
- 2004-11-30 RU RU2006124513/04A patent/RU2354651C2/ru not_active IP Right Cessation
- 2004-11-30 CN CNB2004800368183A patent/CN100532369C/zh not_active Expired - Fee Related
- 2004-11-30 DE DE602004008668T patent/DE602004008668T2/de active Active
- 2004-11-30 JP JP2006543432A patent/JP4527730B2/ja not_active Expired - Fee Related
- 2004-11-30 CA CA002547764A patent/CA2547764A1/en not_active Abandoned
- 2004-11-30 BR BRPI0416873-9A patent/BRPI0416873A/pt not_active Application Discontinuation
- 2004-11-30 KR KR1020067011286A patent/KR100827915B1/ko not_active IP Right Cessation
- 2004-11-30 EP EP04820410A patent/EP1694656B1/en active Active
- 2004-12-07 MY MYPI20045047A patent/MY145576A/en unknown
- 2004-12-07 AR ARP040104555A patent/AR046753A1/es not_active Application Discontinuation
- 2004-12-08 TW TW093137995A patent/TW200522953A/zh unknown
- 2004-12-09 US US11/008,310 patent/US7202241B2/en not_active Expired - Fee Related
-
2006
- 2006-05-22 IL IL175817A patent/IL175817A0/en unknown
- 2006-05-31 NO NO20062491A patent/NO20062491L/no not_active Application Discontinuation
- 2006-06-08 ZA ZA200604725A patent/ZA200604725B/xx unknown
- 2006-06-12 CO CO06056964A patent/CO5700768A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20062491L (no) | 2006-09-06 |
| RU2006124513A (ru) | 2008-01-27 |
| DE602004008668T2 (de) | 2008-06-12 |
| ATE371653T1 (de) | 2007-09-15 |
| DE602004008668D1 (de) | 2007-10-11 |
| BRPI0416873A (pt) | 2007-02-27 |
| KR20060097758A (ko) | 2006-09-15 |
| AU2004299201A1 (en) | 2005-06-30 |
| JP4527730B2 (ja) | 2010-08-18 |
| IL175817A0 (en) | 2006-10-05 |
| CN1890227A (zh) | 2007-01-03 |
| CA2547764A1 (en) | 2005-06-30 |
| AU2004299201B2 (en) | 2009-12-03 |
| NZ547120A (en) | 2009-02-28 |
| US20050124613A1 (en) | 2005-06-09 |
| ZA200604725B (en) | 2007-12-27 |
| EP1694656A1 (en) | 2006-08-30 |
| WO2005058847A1 (en) | 2005-06-30 |
| CO5700768A2 (es) | 2006-11-30 |
| MY145576A (en) | 2012-02-29 |
| ES2291984T3 (es) | 2008-03-01 |
| KR100827915B1 (ko) | 2008-05-07 |
| EP1694656B1 (en) | 2007-08-29 |
| CN100532369C (zh) | 2009-08-26 |
| TW200522953A (en) | 2005-07-16 |
| US7202241B2 (en) | 2007-04-10 |
| RU2354651C2 (ru) | 2009-05-10 |
| JP2007513904A (ja) | 2007-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5700768A2 (es) | Derivados de benzoxazina y sus usos | |
| CO6251243A2 (es) | Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c | |
| AR062666A1 (es) | Benzotriazoles como moduladores de quinasas | |
| CR7950A (es) | Sintesis de los cloruros de 4amino -2butenoilo y su uso en la preparacion of 3- cianoquinolinas | |
| AR081649A1 (es) | Compuestos heteroarilo nitrogenados | |
| CO5580815A2 (es) | Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
| CO5690593A2 (es) | Nuevos derivados de pirimidin 2-amina | |
| PE20220567A1 (es) | Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR069435A1 (es) | Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa | |
| AR036106A1 (es) | Compuestos azaindoles inhibidores de quinasa selectivos, composiciones farmaceuticas y el uso de dicha composicion para la fabricacion de un medicamento | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| AR042668A1 (es) | Derivados de fosfonoxi quinazolinas y su uso farmaceutico | |
| AR069804A1 (es) | Agonistas del receptor glucocorticoide c20- c21 sustituido | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| AR058554A1 (es) | Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5. | |
| AR069796A1 (es) | Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| AR070992A1 (es) | Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1 | |
| AR039988A1 (es) | Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos | |
| AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos | |
| AR077440A1 (es) | Bencenosulfonamidas como bloqueadores de canales de calcio y composiciones farmaceuticas | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| AR057855A1 (es) | Derivados de pirazina y composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |